Back to results
US 11,684,671 B2Granted
Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
AssigneeVrije Universiteit Brussel
InventorsKris Maria Magdalena Thielemans, Aude Bonehill
Life of this patent
Estimating the term…
Abstract
We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TI R4 (caTIR4).
Claims8
A method for the treatment of cancer, comprising intravenously administering to a subject in need thereof:
- one or more isolated mRNA molecule(s) encoding for:
- a functional immunostimulatory protein CD40L, constitutively active TLR4 (caTLR4), and a functional immunostimulatory protein CD70;
- and
- one or more mRNA molecules encoding for a tumor antigen;
- wherein all mRNA molecules encoding for a tumor antigen also encode for an HLA class II targeting sequence of DC-LAMP;
- wherein the method does not include the administration of dendritic cells to the subject;
- wherein the one or more isolated mRNA molecule(s) are protected via liposome-encapsulation;
- and
- wherein said liposome-encapsulation is not mannosylated lipoplexation.
6 more elements
Dependencies are inferred from the claim text.